The estimated Net Worth of Venture Partners Vi Lp Sand... is at least 12.5 百万$ dollars as of 15 March 2013. Venture Sand owns over 250,000 units of Pacira BioSciences Inc stock worth over 5,409,079$ and over the last 12 years Venture sold PCRX stock worth over 7,052,500$.
Venture has made over 1 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Venture sold 250,000 units of PCRX stock worth 7,052,500$ on 15 March 2013.
The largest trade Venture's ever made was selling 250,000 units of Pacira BioSciences Inc stock on 15 March 2013 worth over 7,052,500$. On average, Venture trades about 250,000 units every 0 days since 2013. As of 15 March 2013 Venture still owns at least 416,083 units of Pacira BioSciences Inc stock.
You can see the complete history of Venture Sand stock trades at the bottom of the page.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over 321,391,130$ worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth 15,133,188$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of 491,036$. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth 20,034$.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: